Semaglutide vs Tirzepatide vs Retatrutide: The Complete Comparison

Three medications. Three different mechanisms. Dramatically different results. If you are considering medical weight loss in 2026, understanding the differences between semaglutide, tirzepatide, and retatrutide is the first step in choosing the right option for your body and your goals.

Here is the honest, evidence-based comparison your provider should be giving you.

Quick Comparison Table

Feature	Semaglutide	Tirzepatide	Retatrutide
Receptors targeted	GLP-1	GLP-1 + GIP	GLP-1 + GIP + Glucagon
Brand names	Ozempic, Wegovy	Mounjaro, Zepbound	(investigational)
Average weight loss	~14.9% (STEP 1, 68 wks)	~22.5% (SURMOUNT-1, 72 wks)	~24.2% (Phase 2, 48 wks)
FDA status	Approved	Approved	Phase 3 trials (compounded access)
Dosing frequency	Weekly injection	Weekly injection	Weekly injection
Effect on metabolic rate	Minimal	Modest	Significant increase
Liver fat reduction	Moderate	Significant	Substantial (up to 82%)
Appetite suppression	Strong	Very strong	Very strong
GI side effects	Moderate	Moderate to high	Moderate to high
Clinical experience	Longest	Extensive	Emerging
Best for	Established option, mild-to-moderate weight loss	Maximum efficacy, dual-action	Cutting-edge, plateau breaker

This table summarizes the differences, but the real story requires understanding how each medication works at the mechanism level. That is where the choice between them actually comes into focus.

Semaglutide: The Established Player

How It Works

Semaglutide is a GLP-1 receptor agonist — it mimics the natural hormone GLP-1, which is released by the small intestine after eating. When GLP-1 receptors are activated, four things happen: appetite is suppressed through signals in the hypothalamus and brainstem, gastric emptying slows (keeping you full longer), glucose-dependent insulin release is enhanced, and inappropriate post-meal glucagon release is suppressed. The net effect is that you eat less, feel full on smaller portions, and have better blood sugar regulation.

What the Data Shows

The STEP 1 trial, published in the New England Journal of Medicine in 2021, randomized 1,961 adults with obesity to 2.4 mg weekly semaglutide or placebo for 68 weeks (1). Key results:

• Average weight loss: 14.9 percent (approximately 33 pounds for a 220-pound individual)
• 50 percent of participants lost at least 15 percent of body weight
• 32 percent of participants lost at least 20 percent
• Significant improvements in waist circumference, blood pressure, HbA1c, and quality of life

Brand Names and Availability

Semaglutide is marketed as Ozempic for type 2 diabetes and Wegovy for weight loss. Compounded versions are also widely available through licensed pharmacies, offering cost-effective access under physician supervision.

Best For

• Patients who want a proven, well-studied option with the longest clinical experience
• Patients who have plateaued on other weight loss strategies and need pharmaceutical support for the first time
• Patients with milder obesity or 30 to 50 pounds to lose
• Patients who prioritize cost-effectiveness
• Patients with type 2 diabetes seeking combined glycemic and weight benefits

Read more on the semaglutide service page or our article on what happens when you stop semaglutide.

Tirzepatide: The Dual-Action Upgrade

How It Works

Tirzepatide adds a second receptor — GIP (glucose-dependent insulinotropic polypeptide) — to the GLP-1 pathway. GIP is a second incretin hormone that enhances insulin sensitivity, influences how fat is stored and metabolized in adipose tissue, and works synergistically with GLP-1. When you activate both receptors together, the effects on appetite, glucose regulation, and fat metabolism exceed what either achieves alone.

A study in Cell Metabolism demonstrated that GIP receptor activation in adipose tissue can promote fat oxidation under certain conditions, and the combination of GIP and GLP-1 produces greater weight loss than either alone in both preclinical and clinical trials (2).

What the Data Shows

The SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, randomized 2,539 adults with obesity to tirzepatide at 5, 10, or 15 mg weekly or placebo for 72 weeks (3). Key results:

• 15 mg dose: Average weight loss of 22.5 percent (approximately 52 pounds for a 230-pound individual)
• 10 mg dose: Average weight loss of 21.4 percent
• 5 mg dose: Average weight loss of 16.0 percent
• Over 85 percent of participants at 10 mg or 15 mg lost at least 10 percent of body weight
• Over 50 percent at 15 mg lost at least 20 percent

SURMOUNT-5, a head-to-head trial comparing tirzepatide to semaglutide, confirmed tirzepatide’s superiority at matched doses.

Brand Names and Availability

Tirzepatide is marketed as Mounjaro for type 2 diabetes and Zepbound for weight loss. Compounded versions are also available.

Best For

• Patients who want maximum efficacy with an FDA-approved medication
• Patients who have plateaued on semaglutide and need a stronger option
• Patients with significant weight to lose (50+ pounds)
• Patients with insulin resistance, metabolic syndrome, or type 2 diabetes
• Patients who have the budget for the more expensive option

See our full tirzepatide service page and our deep comparison of the difference between tirzepatide and semaglutide.

Retatrutide: The Next Generation

How It Works

Retatrutide activates three receptors simultaneously — GLP-1, GIP, and glucagon. Adding the glucagon pathway is what sets retatrutide apart.

Glucagon receptor activation does something the other two medications cannot: it increases resting energy expenditure. It raises basal metabolic rate, promotes fat oxidation in the liver (beta-oxidation), and stimulates thermogenesis in brown adipose tissue. The result is that retatrutide does not just help you eat less — it helps you burn more. A study in The Journal of Clinical Investigation demonstrated that glucagon infusion increases energy expenditure by 100 to 200 calories per day (4), and retatrutide replicates this effect through sustained receptor activation.

The simplest way to think about it: semaglutide reduces input. Tirzepatide reduces input more efficiently. Retatrutide reduces input and increases output.

What the Data Shows

The Phase 2 trial of retatrutide, published in the New England Journal of Medicine in 2023, enrolled 338 adults with obesity or overweight with a weight-related condition (5). Key results:

• 12 mg dose: Average weight loss of 24.2 percent of body weight
• 8 mg dose: Average weight loss of 22.8 percent
• 4 mg dose: Average weight loss of 17.0 percent
• Over 90 percent of participants at 8 or 12 mg lost at least 10 percent of body weight
• Over 75 percent at 12 mg lost at least 20 percent

Crucially, the weight loss curve had not yet plateaued at 48 weeks, suggesting longer treatment may produce even greater results. Additionally, a separate Phase 2 trial in type 2 diabetes demonstrated up to 82 percent reduction in liver fat content at the 12 mg dose — results not matched by any other weight loss medication.

Current Status and Availability

Retatrutide is in Phase 3 trials (Eli Lilly’s TRIUMPH program) and is not yet FDA-approved. Some patients access retatrutide through compounding pharmacies under physician supervision. We have been offering retatrutide therapy since it became available through compounding — see our detailed post on how retatrutide works for more on the mechanism.

Best For

• Patients who have plateaued on semaglutide or tirzepatide
• Patients with significant weight to lose (50+ pounds)
• Patients with fatty liver disease (MASLD/NAFLD) or metabolic syndrome
• Patients who want access to the most advanced mechanism currently available
• Patients with established GLP-1 experience and good tolerance

Side Effect Comparison

All three medications share a similar side effect profile driven primarily by gastrointestinal effects:

Common Side Effects (All Three)

• Nausea — most common during dose escalation, usually resolves within 2 to 4 weeks at each dose level
• Diarrhea — reported by 15 to 25 percent of patients
• Vomiting — reported by 8 to 15 percent
• Constipation — reported by 6 to 12 percent
• Decreased appetite — nearly universal and considered therapeutic

Tirzepatide and retatrutide may have slightly higher rates of GI side effects than semaglutide due to the additional pathway activation. Individual response varies considerably — some patients tolerate retatrutide better than semaglutide and vice versa.

Minimizing Side Effects

Our standard approach minimizes side effects through:

1. Gradual dose titration — not rushing the escalation schedule is the single most important factor in tolerability
2. Adequate hydration and fiber — helps manage GI effects
3. Protein-forward nutrition — 0.7 to 1.0 grams per pound of ideal body weight daily, distributed across meals
4. Patient education — knowing what to expect and when to call us
5. Side effect mitigation medications when needed

Most patients experience some side effects during the first few weeks, and most find them manageable with the approaches above.

Rare But Serious Risks

All three medications carry a class warning regarding medullary thyroid carcinoma based on rodent studies. Pancreatitis is rare but possible. Gallbladder disease is associated with rapid weight loss from any cause. Appropriate screening before starting treatment and ongoing monitoring throughout treatment are essential.

How We Help You Choose

Choosing between these three medications is not about which is “best” in the abstract — it is about which is best for you.

Factors We Consider

Prior weight loss experience. Have you tried GLP-1 therapy before? If so, what dose, for how long, and what results? Patients new to GLP-1s typically start with semaglutide or tirzepatide. Patients who have plateaued on a previous medication are candidates for the next step up.

Metabolic health profile. Do you have insulin resistance, prediabetes, fatty liver disease, or metabolic syndrome? These conditions often benefit specifically from tirzepatide or retatrutide due to the broader metabolic effects.

Total weight loss target. The larger your target, the more meaningful the incremental advantage of tirzepatide or retatrutide becomes.

Budget and cost-effectiveness. All three medications have significant cost considerations. Compounded versions can reduce costs substantially. We help you understand the full cost picture before starting treatment.

Side effect tolerance. Patients with a history of sensitive GI systems may do better starting with semaglutide and escalating if needed.

Medical history. Contraindications, medication interactions, and individual risk factors determine which options are appropriate for you.

The Role of Comprehensive Labs

Before starting any of these medications, we run comprehensive lab work including fasting insulin and HOMA-IR, HbA1c, complete metabolic panel, liver function, lipids, and thyroid. This reveals whether you have insulin resistance that benefits particularly from tirzepatide or retatrutide, whether you have elevated liver fat that benefits from retatrutide’s glucagon pathway, and whether there are any contraindications we need to address before starting.

Nutrition and Exercise Still Matter

Any GLP-1 medication works better when combined with adequate protein intake, resistance training, and lifestyle changes. The medication makes eating less easier, but it does not automatically build muscle or protect bone density during rapid weight loss. Protein-forward nutrition and strength training are essential companions to any medical weight loss protocol.

Getting Started

If you are considering medical weight loss, the first step is a conversation. Take our quick quiz to get a personalized recommendation, or schedule a consultation to discuss your specific goals, medical history, and the right option for you.

At Rewind Anti-Aging of Miami, we offer all three medications — semaglutide, tirzepatide, and retatrutide — through a comprehensive medical weight loss program built around lab-based decision-making, personalized titration, and ongoing clinical support.

Related Articles

• How Does Retatrutide Work? The Triple-Action Peptide Explained
• What Is Retatrutide? The Triple-Agonist Changing Weight Loss in 2026
• The Difference Between Tirzepatide and Semaglutide
• Is Semaglutide the Same as Ozempic?

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.
2. Samms RJ, Sloop KW, Gribble FM, et al. GIPR function in the central nervous system: plausible or preposterous? Trends Endocrinol Metab. 2021;32(1):30-42.
3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.
4. Nair KS. Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency. J Clin Endocrinol Metab. 1987;64(5):896-901.
5. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526.

---

Ready to find the right medication for you? Rewind Anti-Aging of Miami offers personalized medical weight loss therapy with all three medications. Take our quiz or schedule a consultation →